Skip to main content
. 2019 Jun 4;20(9):1172–1175. doi: 10.1080/15384047.2019.1617561

Figure 1.

Figure 1.

Tumor lesions detected by PET-CT. (a). Before the start of TKI treatment: central lung tumor in the left lower lobe mass infiltrating the hilum and mediastinum and bilateral adrenal metastases; (b). Progression after 6 months of erlotinib: enlarged pleural mass that showed transformation to SCLC. (c) Partial response after four cycles of EP chemotherapy and erlotinib continuation: Dramatic shrinkage of the primary lung tumor.